Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

PET/CT Imaging of Malignant Brain Tumors With 124I-NM404

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University of Wisconsin, Madison
ClinicalTrials.gov Identifier:
NCT01516905
First received: January 10, 2012
Last updated: November 23, 2016
Last verified: November 2016

January 10, 2012
November 23, 2016
December 2011
January 2017   (final data collection date for primary outcome measure)
tumor to background ratios [ Time Frame: 48hrs ] [ Designated as safety issue: No ]
patients will be imaged at 3 different times out to 48 hrs post injection. Images will be evaluated based on tumor/background, dimensions/volumes and a qualitative score
Determine the optimal imaging parameters (dose, acquisition time, imaging time post injection, tumor dosimetry) of 124I-NM404 PET/CT in patients with brain metastasis [ Time Frame: 48hrs ] [ Designated as safety issue: No ]
patients will be imaged at 3 different timepoints 6hrs,24 hrs and 48 hrs. Images will be evaluated based on tumor/background, dimensions/volumes and a qualitative score
Complete list of historical versions of study NCT01516905 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
PET/CT Imaging of Malignant Brain Tumors With 124I-NM404
PET/CT Imaging of Malignant Brain Tumors With a Novel Radioiodinated Phospholipid Ether Analogue 124I-NM404
The purpose of this study is to evaluate diagnostic imaging techniques using 124I-NM404 PET/CT in humans with brain metastases and GBMs. This goal will be accomplished by determining the optimal PET/CT protocol and comparing PET tumor uptake to MRI and calculating tumor dosimetry. A future aim of this study will be to compare non-invasive PET/CT and MRI findings with pathological specimens, which is the gold standard but is invasive and impractical in many cases, to determine the sensitivity and specificity of both techniques for accurately detecting tumor infiltration. The data obtained from this study will be used to develop larger diagnostic and therapeutic trials in brain tumors. The long-term goals of this research are to improve the diagnosis and treatment of malignant brain tumors by using radioiodinated NM404.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Subjects will be recruited when seen by oncologists in the UWCCC clinic.
  • Glioblastoma
  • Brain Metastases
Drug: NM404
injection of either 2.0mCi or 5.0mCi I-124 NM404
Other Name: PET imaging with I-124 NM404
I124-NM404 brain metastases or GBM imaging
determining appropriate imaging timepoints. Image at 6 hour, 24 hour and 48 hour post injection of I-124NM404
Intervention: Drug: NM404
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
19
January 2017
January 2017   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Participants will have a contrast enhanced brain MRI which documents evidence of GBM or metastatic brain tumor
  2. Tumor size at least 1.5 cm in greatest axial dimension on MRI. MRI must be obtained within 2 months of study inclusion
  3. Female patients must not be pregnant or breast feeding and both women of childbearing potential, and men, must use appropriate means of contraception and must be maintained for at least 45 days after injection of I-124 NM404. Participants must not attempt to become pregnant during this time
  4. Platelet count must be ≥ 160,000/µl, Hematocrit must be ≥ 22%, Leukocyte count must be ≥ 3,000/µL, Creatinine must be ≤ 2.5 mg/dL, ALT must be ≤ 130 U/L, AST must be ≤ 100 U/L, and urine or serum pregnancy test must be negative for pregnancy
  5. Karnofsky score ≥ 60
  6. For brain metastases patients: targeted brain therapy (radiation or drug) must have concluded ≥2 months prior to injection of 124I-NM404
  7. For GBM tumors confirmed by surgical biopsy or suspected by MRI: no previous surgical resection (except for biopsy) or systemic or radiation therapy targeted to the GBM tumor -

Exclusion Criteria:

  1. Life expectancy of < 3 months
  2. Allergy to potassium iodide (SSKI or Thyroshield)
  3. Planned surgical resection or biopsy after injection of 124I-NM404 and prior to completion of the 3rd PET/CT scan
  4. Unwilling or unable to complete 3 separate PET/CT imaging sessions of 90 minutes each over 3 days -
Both
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01516905
RO11310, 1R01CA158800-01
Yes
Not Provided
Not Provided
University of Wisconsin, Madison
University of Wisconsin, Madison
National Cancer Institute (NCI)
Principal Investigator: Lance Hall, MD University of Wisconsin, Madison
Principal Investigator: Scott Perlman, MD, MS University of Wisconsin, Madison
University of Wisconsin, Madison
November 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP